Leerink Partnrs Brokers Increase Earnings Estimates for RXRX

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) – Equities researchers at Leerink Partnrs upped their FY2024 earnings estimates for Recursion Pharmaceuticals in a report released on Wednesday, November 6th. Leerink Partnrs analyst M. Foroohar now expects that the company will earn ($1.45) per share for the year, up from their previous forecast of ($1.57). The consensus estimate for Recursion Pharmaceuticals’ current full-year earnings is ($1.54) per share. Leerink Partnrs also issued estimates for Recursion Pharmaceuticals’ Q4 2024 earnings at ($0.33) EPS and FY2025 earnings at ($1.40) EPS.

Recursion Pharmaceuticals (NASDAQ:RXRX) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by ($0.01). Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The company had revenue of $26.08 million for the quarter, compared to the consensus estimate of $12.62 million. During the same quarter in the previous year, the business earned ($0.43) earnings per share. Recursion Pharmaceuticals’s revenue was up 147.6% compared to the same quarter last year.

RXRX has been the topic of a number of other reports. Leerink Partners cut their price objective on Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating on the stock in a research report on Tuesday, September 3rd. Jefferies Financial Group reduced their price objective on shares of Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating on the stock in a research report on Tuesday, September 3rd. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $11.00 target price on shares of Recursion Pharmaceuticals in a research report on Thursday, November 7th. Four analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $9.40.

Recursion Pharmaceuticals Stock Up 10.4 %

Shares of Recursion Pharmaceuticals stock opened at $7.84 on Monday. The stock has a market capitalization of $2.20 billion, a price-to-earnings ratio of -5.12 and a beta of 0.81. The company has a debt-to-equity ratio of 0.04, a quick ratio of 6.07 and a current ratio of 4.35. The company’s 50 day moving average price is $6.58 and its 200-day moving average price is $7.62. Recursion Pharmaceuticals has a 52-week low of $5.22 and a 52-week high of $15.74.

Insiders Place Their Bets

In related news, Director Blake Borgeson sold 11,447 shares of the stock in a transaction that occurred on Tuesday, October 29th. The shares were sold at an average price of $6.72, for a total value of $76,923.84. Following the completion of the sale, the director now directly owns 7,077,560 shares of the company’s stock, valued at approximately $47,561,203.20. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In other Recursion Pharmaceuticals news, Director Blake Borgeson sold 11,447 shares of the company’s stock in a transaction that occurred on Tuesday, October 29th. The stock was sold at an average price of $6.72, for a total value of $76,923.84. Following the completion of the transaction, the director now directly owns 7,077,560 shares in the company, valued at $47,561,203.20. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Christopher Gibson sold 20,000 shares of the business’s stock in a transaction on Wednesday, September 4th. The stock was sold at an average price of $6.04, for a total transaction of $120,800.00. Following the completion of the sale, the chief executive officer now owns 762,656 shares in the company, valued at approximately $4,606,442.24. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 156,682 shares of company stock worth $1,012,618. Company insiders own 15.75% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Intech Investment Management LLC purchased a new position in shares of Recursion Pharmaceuticals during the third quarter worth approximately $349,000. KBC Group NV increased its holdings in Recursion Pharmaceuticals by 79.9% during the 3rd quarter. KBC Group NV now owns 7,602 shares of the company’s stock worth $50,000 after purchasing an additional 3,377 shares during the period. Pier 88 Investment Partners LLC raised its position in Recursion Pharmaceuticals by 442.1% during the 3rd quarter. Pier 88 Investment Partners LLC now owns 133,910 shares of the company’s stock valued at $882,000 after purchasing an additional 109,210 shares in the last quarter. Victory Capital Management Inc. lifted its holdings in shares of Recursion Pharmaceuticals by 25.1% in the 3rd quarter. Victory Capital Management Inc. now owns 27,394 shares of the company’s stock worth $181,000 after buying an additional 5,503 shares during the period. Finally, Axxcess Wealth Management LLC raised its holdings in shares of Recursion Pharmaceuticals by 4.3% in the third quarter. Axxcess Wealth Management LLC now owns 43,884 shares of the company’s stock valued at $289,000 after acquiring an additional 1,795 shares in the last quarter. Institutional investors own 89.06% of the company’s stock.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.